Archives
- 2018-07
- 2018-10
- 2018-11
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
-
br O GlcNAcase Human OGA is
2019-09-20
O-GlcNAcase Human OGA is a multidomain protein with an N-terminal domain similar to glycoside hydrolase family 84 (GH84) enzymes, a stalk domain, a C-terminal pseudo histone acetyltransferase (HAT) domain, and several low-complexity regions (Figure 1f) [43]. A splice variant that lacks the HAT do
-
PI K Akt eNOS signaling is long
2019-09-20
PI3K-Akt-eNOS signaling is long been known as a cell survival pathway in cardiology [8]. Current study has shown that ginsenosides, which is demonstrated to exhibit cardioprotective effect in several aspects, prevented cardiac ischemia/reperfusion injury via upregulation of PI3K and phosphorylations
-
The TELI results of DNA
2019-09-19
The TELI results of DNA damage responses to CAA and SO then informed our choice of bacterial strains in subsequent experiments. We investigated E. coli cellular survival in response to CAA and SO exposure by determining the sensitivity of a number of E. coli strains, each possessing single or multip
-
Nitric oxide NO is synthesized by conversion of the l
2019-09-19
Nitric oxide (NO) is synthesized by conversion of the l-arginine to NO and l-citrulline through reaction which is catalyzed by nitric oxide synthetase (NOS) (Knowles and Moncada, 1994). NO as an important molecule not only play a role as second messenger but also binds to cytochrome c oxidase and de
-
In our opinion the precise
2019-09-19
In our opinion, the precise function of AE of S. mansoni (Sm32) remains unclear, and accurate knowledge of the three dimensional structure of this enzyme would be valuable for a better understanding the molecular basis of many of its properties, including its role in the host-parasite interaction, a
-
Imatinib STI is a first line tyrosine kinase inhibitor
2019-09-19
Imatinib (STI-571) is a first-line tyrosine kinase inhibitor (TKI) targeted at breakpoint cluster region-Abelson kinase (ABL) for the treatment of chronic myeloid leukemia (CML) [26]. As a type II inhibitor, imatinib achieves significant selectivity by binding to an inactive DFG-out conformation (DF
-
br Deubiquitination deubiquitinases and cancer Protein deubi
2019-09-19
Deubiquitination, deubiquitinases and cancer Protein deubiquitination is reverse process of ubiquitination and performed by deubiquitinases or deubiquitinating enzymes (DUBs), which help in removal of ubiquitin from target proteins and involve in ubiquitin maturation, recycling and editing (Pfoh
-
br Endothelial mechanotransduction br Apoptosis br Death ass
2019-09-19
Endothelial mechanotransduction Apoptosis Death associated protein kinase Conclusion DAPK is localized to the Ryuvidine network, and promotes actomyosin contractility. DAPK stabilizes stress fibers by phosphorylation of MLC (Bialik et al., 2004, Kuo et al., 2003). In endothelial cells D
-
In conclusion our data demonstrated
2019-09-19
In conclusion, our data demonstrated that montelukast and pranlukast non-competitively blocked P2Y signaling in several cell systems, but in a relatively nonsubtype-specific manner. The functional antagonism was especially evident at heterologously expressed P2Y1 and P2Y6 receptors, at which IC50 va
-
Currently no evidence supports pathogenic variants in exons
2019-09-19
Currently, no evidence supports pathogenic variants in exons 20, 21, and 22, which are part of transcript isoform hCDKL5_5, or within exon 17, which is part of transcript isoform hCDKL5_2. The pathogenicity of variants in the 5′ untranslated region remain uncertain except for deletions extending to
-
NU 1025 clinical hUcn II influence on MAP is
2019-09-19
hUcn II influence on MAP is mediated by the activation of CRF2 receptors. In vitro binding studies established that hUcn II is a selective ligand for CRF2 receptors with a slightly higher affinities for CRF2β compared with CRF2α and low or no affinity for CRF1 receptor [13], [19], [24]. Recent in vi
-
Preparation of the pyridyl ether analogs
2019-09-19
Preparation of the 2-pyridyl ether analogs (–) was accomplished by alkylation of alcohol with 2-bromopyridines in the presence of NaH to afford the desired pyridyl ether analogs in low to moderate yield. Preparation of the 3-pyridyl analog was carried out by conversion of alcohol to the tosylate,
-
br Conclusion br Acknowledgements br Introduction
2019-09-19
Conclusion Acknowledgements Introduction In recent years, fast progress has been made toward using the supercritical technology in industrial separation processes. Apart from a green extraction process that replaces organic solvents, applications involving supercritical fluids include super
-
Results from experiments in model
2019-09-18
Results from experiments in model systems have suggested that the DPRs translated from the HRE of C9ORF72 are toxic and play a role in disease pathogenesis (reviewed in Taylor et al. (2016)). Although the DPRs are present in neurons and glia in various regions of the central nervous system (CNS) ear
-
br Conclusions br Acknowledgements br Introduction Liver can
2019-09-18
Conclusions Acknowledgements Introduction Liver cancer was the fifth most common cancer and the second leading cause of cancer-related death worldwide [1]. Most of primary liver cancers (70–90%) occurring worldwide are hepatocellular carcinoma (HCC) [2]. Persistent hepatitis B virus (HBV) i
16254 records 974/1084 page Previous Next First page 上5页 971972973974975 下5页 Last page